Global Targeted Drugs for Neurodegenerative Diseases Market 2026 by Company, Regions, Type and Application, Forecast to 2032
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Classification of Targeted Drugs for Neurodegenerative Diseases by Type
- 1.3.1 Overview: Global Targeted Drugs for Neurodegenerative Diseases Market Size by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Global Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Type in 2025
- 1.3.3 Injection
- 1.3.4 Oral
- 1.4 Global Targeted Drugs for Neurodegenerative Diseases Market by Application
- 1.4.1 Overview: Global Targeted Drugs for Neurodegenerative Diseases Market Size by Application: 2021 Versus 2025 Versus 2032
- 1.4.2 Parkinson's Disease (PD)
- 1.4.3 Alzheimer's Disease (AD)
- 1.4.4 Huntington's Disease (HD)
- 1.4.5 Tardive Dyskinesia (TD)
- 1.4.6 Multiple Sclerosis (MS)
- 1.5 Global Targeted Drugs for Neurodegenerative Diseases Market Size & Forecast
- 1.6 Global Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast by Region
- 1.6.1 Global Targeted Drugs for Neurodegenerative Diseases Market Size by Region: 2021 VS 2025 VS 2032
- 1.6.2 Global Targeted Drugs for Neurodegenerative Diseases Market Size by Region, (2021-2032)
- 1.6.3 North America Targeted Drugs for Neurodegenerative Diseases Market Size and Prospect (2021-2032)
- 1.6.4 Europe Targeted Drugs for Neurodegenerative Diseases Market Size and Prospect (2021-2032)
- 1.6.5 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size and Prospect (2021-2032)
- 1.6.6 South America Targeted Drugs for Neurodegenerative Diseases Market Size and Prospect (2021-2032)
- 1.6.7 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size and Prospect (2021-2032)
2 Company Profiles
- 2.1 Acadia Pharmaceuticals Inc.
- 2.1.1 Acadia Pharmaceuticals Inc. Details
- 2.1.2 Acadia Pharmaceuticals Inc. Major Business
- 2.1.3 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Product and Solutions
- 2.1.4 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 Acadia Pharmaceuticals Inc. Recent Developments and Future Plans
- 2.2 Kyowa Kirin
- 2.2.1 Kyowa Kirin Details
- 2.2.2 Kyowa Kirin Major Business
- 2.2.3 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Product and Solutions
- 2.2.4 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 Kyowa Kirin Recent Developments and Future Plans
- 2.3 Supernus Pharmaceuticals
- 2.3.1 Supernus Pharmaceuticals Details
- 2.3.2 Supernus Pharmaceuticals Major Business
- 2.3.3 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Product and Solutions
- 2.3.4 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 Supernus Pharmaceuticals Recent Developments and Future Plans
- 2.4 UCB
- 2.4.1 UCB Details
- 2.4.2 UCB Major Business
- 2.4.3 UCB Targeted Drugs for Neurodegenerative Diseases Product and Solutions
- 2.4.4 UCB Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
- 2.4.5 UCB Recent Developments and Future Plans
- 2.5 Sumitomo Pharma
- 2.5.1 Sumitomo Pharma Details
- 2.5.2 Sumitomo Pharma Major Business
- 2.5.3 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Product and Solutions
- 2.5.4 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
- 2.5.5 Sumitomo Pharma Recent Developments and Future Plans
- 2.6 Biogen
- 2.6.1 Biogen Details
- 2.6.2 Biogen Major Business
- 2.6.3 Biogen Targeted Drugs for Neurodegenerative Diseases Product and Solutions
- 2.6.4 Biogen Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
- 2.6.5 Biogen Recent Developments and Future Plans
- 2.7 Eisai Inc.
- 2.7.1 Eisai Inc. Details
- 2.7.2 Eisai Inc. Major Business
- 2.7.3 Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Product and Solutions
- 2.7.4 Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
- 2.7.5 Eisai Inc. Recent Developments and Future Plans
- 2.8 Eli Lilly
- 2.8.1 Eli Lilly Details
- 2.8.2 Eli Lilly Major Business
- 2.8.3 Eli Lilly Targeted Drugs for Neurodegenerative Diseases Product and Solutions
- 2.8.4 Eli Lilly Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
- 2.8.5 Eli Lilly Recent Developments and Future Plans
- 2.9 Green Valley
- 2.9.1 Green Valley Details
- 2.9.2 Green Valley Major Business
- 2.9.3 Green Valley Targeted Drugs for Neurodegenerative Diseases Product and Solutions
- 2.9.4 Green Valley Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
- 2.9.5 Green Valley Recent Developments and Future Plans
- 2.10 NOVARTIS
- 2.10.1 NOVARTIS Details
- 2.10.2 NOVARTIS Major Business
- 2.10.3 NOVARTIS Targeted Drugs for Neurodegenerative Diseases Product and Solutions
- 2.10.4 NOVARTIS Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
- 2.10.5 NOVARTIS Recent Developments and Future Plans
- 2.11 Bristol-Myers Squibb
- 2.11.1 Bristol-Myers Squibb Details
- 2.11.2 Bristol-Myers Squibb Major Business
- 2.11.3 Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Product and Solutions
- 2.11.4 Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
- 2.11.5 Bristol-Myers Squibb Recent Developments and Future Plans
- 2.12 Janssen
- 2.12.1 Janssen Details
- 2.12.2 Janssen Major Business
- 2.12.3 Janssen Targeted Drugs for Neurodegenerative Diseases Product and Solutions
- 2.12.4 Janssen Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
- 2.12.5 Janssen Recent Developments and Future Plans
- 2.13 Sanofi
- 2.13.1 Sanofi Details
- 2.13.2 Sanofi Major Business
- 2.13.3 Sanofi Targeted Drugs for Neurodegenerative Diseases Product and Solutions
- 2.13.4 Sanofi Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
- 2.13.5 Sanofi Recent Developments and Future Plans
- 2.14 Roche
- 2.14.1 Roche Details
- 2.14.2 Roche Major Business
- 2.14.3 Roche Targeted Drugs for Neurodegenerative Diseases Product and Solutions
- 2.14.4 Roche Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
- 2.14.5 Roche Recent Developments and Future Plans
- 2.15 Neurocrine
- 2.15.1 Neurocrine Details
- 2.15.2 Neurocrine Major Business
- 2.15.3 Neurocrine Targeted Drugs for Neurodegenerative Diseases Product and Solutions
- 2.15.4 Neurocrine Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
- 2.15.5 Neurocrine Recent Developments and Future Plans
- 2.16 Lundbeck
- 2.16.1 Lundbeck Details
- 2.16.2 Lundbeck Major Business
- 2.16.3 Lundbeck Targeted Drugs for Neurodegenerative Diseases Product and Solutions
- 2.16.4 Lundbeck Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
- 2.16.5 Lundbeck Recent Developments and Future Plans
- 2.17 Teva
- 2.17.1 Teva Details
- 2.17.2 Teva Major Business
- 2.17.3 Teva Targeted Drugs for Neurodegenerative Diseases Product and Solutions
- 2.17.4 Teva Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
- 2.17.5 Teva Recent Developments and Future Plans
3 Market Competition, by Players
- 3.1 Global Targeted Drugs for Neurodegenerative Diseases Revenue and Share by Players (2021-2026)
- 3.2 Market Share Analysis (2025)
- 3.2.1 Market Share of Targeted Drugs for Neurodegenerative Diseases by Company Revenue
- 3.2.2 Top 3 Targeted Drugs for Neurodegenerative Diseases Players Market Share in 2025
- 3.2.3 Top 6 Targeted Drugs for Neurodegenerative Diseases Players Market Share in 2025
- 3.3 Targeted Drugs for Neurodegenerative Diseases Market: Overall Company Footprint Analysis
- 3.3.1 Targeted Drugs for Neurodegenerative Diseases Market: Region Footprint
- 3.3.2 Targeted Drugs for Neurodegenerative Diseases Market: Company Product Type Footprint
- 3.3.3 Targeted Drugs for Neurodegenerative Diseases Market: Company Product Application Footprint
- 3.4 New Market Entrants and Barriers to Market Entry
- 3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
- 4.1 Global Targeted Drugs for Neurodegenerative Diseases Consumption Value and Market Share by Type (2021-2026)
- 4.2 Global Targeted Drugs for Neurodegenerative Diseases Market Forecast by Type (2027-2032)
5 Market Size Segment by Application
- 5.1 Global Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Application (2021-2026)
- 5.2 Global Targeted Drugs for Neurodegenerative Diseases Market Forecast by Application (2027-2032)
6 North America
- 6.1 North America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2021-2032)
- 6.2 North America Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2021-2032)
- 6.3 North America Targeted Drugs for Neurodegenerative Diseases Market Size by Country
- 6.3.1 North America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Country (2021-2032)
- 6.3.2 United States Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
- 6.3.3 Canada Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
- 6.3.4 Mexico Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
7 Europe
- 7.1 Europe Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2021-2032)
- 7.2 Europe Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2021-2032)
- 7.3 Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Country
- 7.3.1 Europe Targeted Drugs for Neurodegenerative Diseases Consumption Value by Country (2021-2032)
- 7.3.2 Germany Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
- 7.3.3 France Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
- 7.3.4 United Kingdom Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
- 7.3.5 Russia Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
- 7.3.6 Italy Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
8 Asia-Pacific
- 8.1 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2021-2032)
- 8.2 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2021-2032)
- 8.3 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size by Region
- 8.3.1 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Consumption Value by Region (2021-2032)
- 8.3.2 China Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
- 8.3.3 Japan Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
- 8.3.4 South Korea Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
- 8.3.5 India Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
- 8.3.6 Southeast Asia Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
- 8.3.7 Australia Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
9 South America
- 9.1 South America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2021-2032)
- 9.2 South America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2021-2032)
- 9.3 South America Targeted Drugs for Neurodegenerative Diseases Market Size by Country
- 9.3.1 South America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Country (2021-2032)
- 9.3.2 Brazil Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
- 9.3.3 Argentina Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
10 Middle East & Africa
- 10.1 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2021-2032)
- 10.2 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2021-2032)
- 10.3 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Country
- 10.3.1 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Consumption Value by Country (2021-2032)
- 10.3.2 Turkey Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
- 10.3.3 Saudi Arabia Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
- 10.3.4 UAE Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
11 Market Dynamics
- 11.1 Targeted Drugs for Neurodegenerative Diseases Market Drivers
- 11.2 Targeted Drugs for Neurodegenerative Diseases Market Restraints
- 11.3 Targeted Drugs for Neurodegenerative Diseases Trends Analysis
- 11.4 Porters Five Forces Analysis
- 11.4.1 Threat of New Entrants
- 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry
12 Industry Chain Analysis
- 12.1 Targeted Drugs for Neurodegenerative Diseases Industry Chain
- 12.2 Targeted Drugs for Neurodegenerative Diseases Upstream Analysis
- 12.3 Targeted Drugs for Neurodegenerative Diseases Midstream Analysis
- 12.4 Targeted Drugs for Neurodegenerative Diseases Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
- 14.1 Methodology
- 14.2 Research Process and Data Source
According to our (Global Info Research) latest study, the global Targeted Drugs for Neurodegenerative Diseases market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
This report is a detailed and comprehensive analysis for global Targeted Drugs for Neurodegenerative Diseases market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Targeted Drugs for Neurodegenerative Diseases market size and forecasts, in consumption value ($ Million), 2021-2032
Global Targeted Drugs for Neurodegenerative Diseases market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Targeted Drugs for Neurodegenerative Diseases market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Targeted Drugs for Neurodegenerative Diseases market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Targeted Drugs for Neurodegenerative Diseases
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Targeted Drugs for Neurodegenerative Diseases market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Acadia Pharmaceuticals Inc., Kyowa Kirin, Supernus Pharmaceuticals, UCB, Sumitomo Pharma, Biogen, Eisai Inc., Eli Lilly, Green Valley, NOVARTIS, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Targeted Drugs for Neurodegenerative Diseases market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Injection
Oral
Market segment by Application
Parkinson's Disease (PD)
Alzheimer's Disease (AD)
Huntington's Disease (HD)
Tardive Dyskinesia (TD)
Multiple Sclerosis (MS)
Market segment by players, this report covers
Acadia Pharmaceuticals Inc.
Kyowa Kirin
Supernus Pharmaceuticals
UCB
Sumitomo Pharma
Biogen
Eisai Inc.
Eli Lilly
Green Valley
NOVARTIS
Bristol-Myers Squibb
Janssen
Sanofi
Roche
Neurocrine
Lundbeck
Teva
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Targeted Drugs for Neurodegenerative Diseases product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Targeted Drugs for Neurodegenerative Diseases, with revenue, gross margin, and global market share of Targeted Drugs for Neurodegenerative Diseases from 2021 to 2026.
Chapter 3, the Targeted Drugs for Neurodegenerative Diseases competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Targeted Drugs for Neurodegenerative Diseases market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Targeted Drugs for Neurodegenerative Diseases.
Chapter 13, to describe Targeted Drugs for Neurodegenerative Diseases research findings and conclusion.